Trial reportAmerican journal of physiology. Gastrointestinal and liver physiology2017
Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
Trial report in American journal of physiology. Gastrointestinal and liver physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 54 citations in OpenAlex.
- Current Concepts in Gastroparesis and Gastric Neuromuscular Disorders-Pathophysiology, Diagnosis, and Management.Diagnostics (Basel, Switzerland) · 2025Review
- Pharmacologic treatments for gastroparesis.Pharmacological reviews · 2025Review
- Gastric emptying after distal gastrectomy from physiologic viewpoint: accelerated or delayed?Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi · 2025Review
- Reconsideration of the Gastroparetic Syndrome.Current gastroenterology reports · 2023Review
- Gastrointestinal motility disorders in patients with multiple sclerosis: A single-center study.Neurogastroenterology and motility · 2022Review
- Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.Frontiers in pharmacology · 2022Review
- Gastroparesis.Gastroenterology · 2022Review
- Management of Gastroparesis.Gastroenterology & hepatology · 2021Article
- New Drugs on the Horizon for Functional and Motility Gastrointestinal Disorders.Gastroenterology · 2021Review
- A North American perspective on the ESNM consensus statement on gastroparesis.Neurogastroenterology and motility · 2021Review
- Gastric accommodation influences proximal gastric and total gastric emptying in concurrent measurements conducted in healthy volunteers.American journal of physiology. Gastrointestinal and liver physiology · 2021Article
- Relationship of motor mechanisms to gastroparesis symptoms: toward individualized treatment.American journal of physiology. Gastrointestinal and liver physiology · 2021Article
- New Developments in Prokinetic Therapy for Gastric Motility Disorders.Frontiers in pharmacology · 2021Review
- Associations of gastric volumes, ingestive behavior, calorie and volume intake, and fullness in obesity.American journal of physiology. Gastrointestinal and liver physiology · 2020Article
- Design and Characterization of Phosphatidylcholine-Based Solid Dispersions of Aprepitant for Enhanced Solubility and Dissolution.Pharmaceutics · 2020Article
- Review
- Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.Journal of the Endocrine Society · 2019Article
- Gastroparesis.Nature reviews. Disease primers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. The effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear; a single, crossover study did not show a significant effect of aprepitant on gastrointestinal transit. Our aim was to compare, in a randomized, double-blind, placebo-controlled, parallel-group study (12 healthy volunteers per group), the effects of aprepitant vs. placebo on gastric emptying of solids (by scintigraphy) with a 320-kcal meal, gastric volumes (GVs; fasting and accommodation by single photon emission-computed tomography ), satiation [maximum tolerated volume (MTV)], and symptoms after a dyspeptogenic meal of Ensure. Aprepitant (125 mg on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.